KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Net Margin (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Net Margin for 16 consecutive years, with 37100.3% as the latest value for Q1 2025.

  • Quarterly Net Margin changed N/A to 37100.3% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 129167.54% through Dec 2025, down 7965810.0% year-over-year, with the annual reading at 129167.54% for FY2025, 7965810.0% down from the prior year.
  • Net Margin hit 37100.3% in Q1 2025 for Inovio Pharmaceuticals, down from 16682.03% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 412.75% in Q3 2022 to a low of 43687.24% in Q4 2022.
  • Historically, Net Margin has averaged 22946.68% across 5 years, with a median of 20627.17% in 2021.
  • Biggest YoY gain for Net Margin was 2021442bps in 2022; the steepest drop was -3094196bps in 2022.
  • Year by year, Net Margin stood at 12745.28% in 2021, then plummeted by -243bps to 43687.24% in 2022, then surged by 44bps to 24357.91% in 2023, then skyrocketed by 32bps to 16682.03% in 2024, then crashed by -122bps to 37100.3% in 2025.
  • Business Quant data shows Net Margin for INO at 37100.3% in Q1 2025, 16682.03% in Q4 2024, and 31648.39% in Q2 2024.